Navigation Links
Polyphenon Pharma Receives Orphan Drug Designation for Its Botanical Drug, Polyphenon E, for the Treatment of CLL
Date:7/28/2008

the United States are diagnosed with CLL.

About Polyphenon Pharma

Polyphenon Pharma is a privately held subsidiary of the Japanese company, Mitsui Norin Co., Ltd., which discovered and manufactures the botanical drug Polyphenon E. Headquartered in New York, NY, Polyphenon Pharma focuses on the clinical development of Polyphenon E across a broad spectrum of therapeutic areas in which it has potential activity, including infectious disease/virology, urology, neurology, and oncology. The Company's two-stage approach to pursuing the full potential of Polyphenon E is to use its own resources to advance drug candidates through Phase II clinical trials or proof-of-concept studies and then seek global pharmaceutical partners to complete late-stage development and commercialization in multiple countries. More information is available at http://www.polyphenon-pharma.com

This press release contains forward-looking statements that involve significant risks and uncertainties. The actual results, performance or achievements of the Company might differ materially from the results, performance or achievements of the Company expressed or implied by such forward-looking statements. Such forward-looking statements include, without limitation, those regarding the development plans of the Company and the expected results of our development. We can provide no assurance that such development will proceed as currently anticipated or that the expected results of such development will be realized. We are subject to various risks, including the uncertainties of clinical trials, drug development and regulatory review, the early stage of our product candidates, our reliance on collaborative partners, our need for additional capital to fund our operations, our history of losses, and other risks inherent to the biopharmaceutical industry.


'/>"/>
SOURCE Polyphenon Pharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
2. Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
3. FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
4. InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
5. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
6. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
7. BioNumerik Pharmaceuticals Observes Evidence of a Survival Increase in Lung Cancer Patients Participating in Tavocept(TM) Clinical Trial
8. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
9. MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion
10. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
11. Edison Pharma Hits Milestone as A0001 Enters Phase 1 Clinical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... Object recognition technology has a unique and ... The VelaSense ® mobile platform incorporates ... productive and fulfilling lives. VelaSense ® will now ... identify objects from a one million object database, that ... databases for personal use. Visus Technology ...
(Date:3/27/2015)... Dynatronics Corporation (NASDAQ: DYNT ) today announced ... the Company,s Board of Directors effective March 23, 2015, to ... of board member Joseph Barton .  ... of Directors represents an important step forward for the company," ... Dynatronics.  "Rich is a proven leader and is well-known for ...
(Date:3/27/2015)... AUGUSTA, Ga. , March 27, 2015  Holographic ... innovator in the field of holographic medical imaging, is ... of its Kickstarter campaign. Launching on April 20 th ... Voxbox and Voxbox Pro. The 8-inch and 22-inch displays ... at home for the first time. In addition to ...
Breaking Medicine Technology:VelaSense Object Recognition Technology for the Blind was unveiled at Baruch College's CCVIP 8th Annual Conference 2Dynatronics Announces Appointment of Richard J. Linder to Board of Directors 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 3
... Pfizer announced today,that Lipitor (atorvastatin calcium) Tablets 80 ... events and major coronary events,in type 2 diabetes ... who had experienced a recent stroke or mini-stroke, ... analysis of the landmark,Stroke Prevention by Aggressive Reduction ...
... 2007 /PRNewswire/ -- Novagali Pharma, an,emerging pharmaceutical company ... phase III clinical trial,positive results from the Phase ... Vernal Keratoconjunctivitis (VKC) at the,XIV Afro-Asian Congress of ... in Marrakech (Morocco). , VKC is a severe ...
Cached Medicine Technology:Lipitor Reduced the Risk of Coronary Events by Half and Stroke by,Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who,Experienced a Recent Stroke 2Lipitor Reduced the Risk of Coronary Events by Half and Stroke by,Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who,Experienced a Recent Stroke 3Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 2Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 3Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 4
(Date:3/29/2015)... (PRWEB) March 29, 2015 Women’s ... menopause treatment. Secondary to their location in Birmingham, ... hospital option. They continue to be affiliated with ... , Menopause is a normal condition that all ... describe any of the changes a woman goes through ...
(Date:3/29/2015)... March 29, 2015 Adults who are ... promote nationally on the web can now use the ... insurance quotes can now be explored while researching the ... , Learning the differences between what a term policy ... a challenge for some men and women. Insurers typically ...
(Date:3/29/2015)... March 29, 2015 The culmination of one ... coming when the Final Four invades Lucas Oil ... has been one filled with excitement, buzzer-beaters, and of course, ... busted, superstars have been made, and future professional products have ... down to the four teams that advanced through their regional ...
(Date:3/29/2015)... March 29, 2015 The Contract ... trials and research, manage data results and help ... clients reach regulation standards. Contract research organizations (CROs) ... device manufacturing sectors. Industry operators provide clients with ... late-stage clinical research for Food and Drug Administration ...
(Date:3/29/2015)... USA (PRWEB) March 29, 2015 ... Link platform provides basic health information around ... opportunity to discuss these challenges as well as ... Health Link addresses six medical conditions using evidenced ... users to engage in conversations around them., ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Affiliates with Beaumont Hospital, Treats Menopause 2Health News:Permanent Life Insurance Quotes Now Offered Through Web Search System at Insurer Website Online 2Health News:Cheap 2015 Final Four Tickets: Ticket Down Slashes Kentucky Wildcats and Wisconsin Badgers Final Four Tickets at Lucas Oil Stadium and Issues Valuable Promo Code 2Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 4Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 2Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 3
... Telesso Technologies Limited, a global healthcare company, announced ... site to enroll patients in a head-to-head trial ... versus the industry,s gold standard device for peripheral ... trial with Vascular Pathways, Inc. 
 

 , ...
... Mass., April 22 Sabertec , an ... , a device designed to reduce CO2 emissions and ... tailpipes while increasing fuel efficiency, took part in a press ... MA Mayor James E. Harrington .At the press conference, ...
... Earnings per Share -- Announces the Acquisition of Cervitech(R) ... up 56.3% from the first quarter 2008 and up ... 81.5% compared to 82.2% for first quarter 2008- GAAP ... of $(0.27) - $(0.25)- First quarter loss per share ...
... and meds could put many at disadvantage, study suggests ... patients may have more difficulty getting dialysis under a ... for Medicare & Medicaid Services will make a single ... injectable medications. These services were previously reimbursed separately. , ...
... boost the ranks of the uninsured , , WEDNESDAY, April 22 ... insurance for a period of time is greater today than ... , These gaps in coverage, however, are shorter than they ... programs, such as Medicaid. , "The bad news is the ...
... IRVINE and DOWNEY, Calif., April 22 Downey ... to outsource its patient financial services to Cymetrix. ... will manage all operations of the DRMC patient ... resolution, from its Los Angeles Business Processing Center.With ...
Cached Medicine News:Health News:Telesso initiates post-market head-to-head peripheral IV catheter study 2Health News:Brockton Mayor, James E. Harrington Calls Press Conference to Unveil Newly Adopted Auto Emissions Technology Acquired With Federal Stimulus Money 2Health News:Brockton Mayor, James E. Harrington Calls Press Conference to Unveil Newly Adopted Auto Emissions Technology Acquired With Federal Stimulus Money 3Health News:NuVasive Reports First Quarter 2009 Financial Results 2Health News:NuVasive Reports First Quarter 2009 Financial Results 3Health News:NuVasive Reports First Quarter 2009 Financial Results 4Health News:NuVasive Reports First Quarter 2009 Financial Results 5Health News:NuVasive Reports First Quarter 2009 Financial Results 6Health News:NuVasive Reports First Quarter 2009 Financial Results 7Health News:NuVasive Reports First Quarter 2009 Financial Results 8Health News:NuVasive Reports First Quarter 2009 Financial Results 9Health News:NuVasive Reports First Quarter 2009 Financial Results 10Health News:NuVasive Reports First Quarter 2009 Financial Results 11Health News:NuVasive Reports First Quarter 2009 Financial Results 12Health News:NuVasive Reports First Quarter 2009 Financial Results 13Health News:NuVasive Reports First Quarter 2009 Financial Results 14Health News:More Americans Experiencing Gaps in Health Coverage 2Health News:More Americans Experiencing Gaps in Health Coverage 3Health News:Downey Regional Medical Center Partners With Cymetrix to Implement Revenue Cycle Solutions 2
... Reichert MK1 Keratometer now utilizes ... consistent lighting, removing the need ... we didnt change are all ... made our Keratometer the worldwide ...
Agglutinating sera for serological identification of E. coli by slide and/or tube agglutination tests. Agglutinating sera are packaged 2 mL / vial....
... The innovative E.coli ... Pro-Lab offers definitive identification ... the use of a ... the possibility of cross-reactions ...
Inquire...
Medicine Products: